Alasdair J Coles

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9449649/publications.pdf

Version: 2024-02-01

108 papers	17,068 citations	47006 47 h-index	29157 104 g-index
112 all docs	112 docs citations	112 times ranked	14587 citing authors

#	Article	IF	Citations
1	Susacâ€™s syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution. Journal of Neurology, 2022, 269, 1695-1697.	3.6	1
2	The impact of smoking cessation on multiple sclerosis disease progression. Brain, 2022, 145, 1368-1378.	7.6	16
3	Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Multiple Sclerosis and Related Disorders, 2022, 57, 103458.	2.0	40
4	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	3.0	13
5	Remyelination in humans due to a retinoidâ€X receptor agonist is ageâ€dependent. Annals of Clinical and Translational Neurology, 2022, 9, 1090-1094.	3.7	10
6	Campath, clones and the cause of autoimmunity. Brain, 2022, 145, 1579-1580.	7.6	1
7	Promoting remyelination in multiple sclerosis. Journal of Neurology, 2021, 268, 30-44.	3.6	79
8	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 107-109.	1.9	38
9	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098213.	3.5	30
10	Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	16
11	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. Journal of Immunology, 2021, 207, 90-100.	0.8	24
12	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders, 2021, 52, 102939.	2.0	34
13	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurology, The, 2021, 20, 709-720.	10.2	44
14	Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet, The, 2021, 398, 1147-1156.	13.7	141
15	Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 295-302.	1.9	15
16	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. Multiple Sclerosis Journal, 2020, 26, 1093-1101.	3.0	6
17	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
18	Guidelines on the use of irradiated blood components. British Journal of Haematology, 2020, 191, 704-724.	2.5	61

#	Article	IF	Citations
19	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
20	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	2.8	63
21	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	10.2	219
22	Hyperpolarized ¹³C MRI: A novel approach for probing cerebral metabolism in health and neurological disease. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1137-1147.	4.3	49
23	Neurological Implications of COVID-19 Infections. Neurocritical Care, 2020, 32, 667-671.	2.4	165
24	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials, 2020, 95, 106009.	1.8	31
25	Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1). Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 365-367.	1.9	19
26	Quantifying normal human brain metabolism using hyperpolarized [1â€“13C]pyruvate and magnetic resonance imaging. NeuroImage, 2019, 189, 171-179.	4.2	144
27	Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2). Trials, 2019, 20, 331.	1.6	7
28	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1273-1288.	3.0	29
29	Antiâ€IL7 receptor Î± monoclonal antibody (GSK2618960) in healthy subjects â€“ a randomized, doubleâ€blind, placeboâ€controlled study. British Journal of Clinical Pharmacology, 2019, 85, 304-315.	2.4	36
30	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
31	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	3.0	57
32	A case of anaphylaxis to alemtuzumab. Journal of Neurology, 2019, 266, 780-781.	3.6	6
33	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. JCI Insight, 2019, 4, .	5.0	16
34	Alemtuzumab as Treatment for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a032029.	6.2	22
35	Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. Brain, 2018, 141, 786-796.	7.6	39
36	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology, 2018, 90, 849-851.	1.1	32

#	Article	IF	Citations
37	Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open, 2018, 8, e025333.	1.9	51
38	Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1779-1782.	3.0	25
39	Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3010-3018.	3.6	57
40	Progressive multifocal leucoencephalopathy with BehÃ§etâ€™s disease: an insight into pathophysiology. Rheumatology, 2017, 56, kew404.	1.9	1
41	Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology, 2017, 88, 1004-1006.	1.1	30
42	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
43	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	188
44	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	232
45	Physician-assisted death should be available to people with MS â€“ Commentary. Multiple Sclerosis Journal, 2017, 23, 1681-1681.	3.0	5
46	Hypothyroid ataxia complicating monoclonal antibody therapy. Practical Neurology, 2017, 17, 482-484.	1.1	4
47	A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers. Journal of Neuroimmunology, 2017, 312, 4-7.	2.3	2
48	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. JCI Insight, 2017, 2, .	5.0	46
49	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 2016, 87, 1985-1992.	1.1	55
50	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon Î²-1a in MS. Neurology, 2016, 87, 1464-1472.	1.1	28
51	Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. Journal of Neurology, 2016, 263, 25-29.	3.6	39
52	Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. Journal of the Neurological Sciences, 2016, 363, 188-194.	0.6	15
53	Clinical relevance of serum antibodies to extracellularN-methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	1.9	97
54	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology, 2015, 15, 273-279.	1.1	169

#	Article	IF	Citations
55	Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 208-215.	1.9	208
56	Newer therapies for multiple sclerosis. Annals of Indian Academy of Neurology, 2015, 18, 30.	0.5	11
57	Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 795-798.	1.9	42
58	Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series. Schizophrenia Research, 2014, 160, 193-195.	2.0	62
59	Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. Journal of Neuroimmunology, 2014, 271, 66-68.	2.3	30
60	Mode of action and clinical studies with alemtuzumab. Experimental Neurology, 2014, 262, 37-43.	4.1	51
61	Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology, 2014, 82, 2158-2164.	1.1	52
62	Product licences for alemtuzumab and multiple sclerosis. Lancet, The, 2014, 383, 867-868.	13.7	8
63	Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 237-243.	2.0	17
64	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. Journal of Neurology, 2013, 260, 462-469.	3.6	27
65	The Outlook for Alemtuzumab in Multiple Sclerosis. BioDrugs, 2013, 27, 181-189.	4.6	6
66	Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology, 2013, 81, 872-876.	1.1	120
67	Alemtuzumab Therapy for Multiple Sclerosis. Neurotherapeutics, 2013, 10, 29-33.	4.4	63
68	Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 60-63.	2.0	32
69	Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain, 2013, 136, 2888-2903.	7.6	174
70	Alemtuzumab Treatment of Multiple Sclerosis. Seminars in Neurology, 2013, 33, 066-073.	1.4	29
71	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20200-20205.	7.1	185
72	Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. Therapeutic Advances in Chronic Disease, 2013, 4, 97-103.	2.5	13

#	Article	IF	Citations
73	Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Multiple Sclerosis Journal, 2013, 19, 241-244.	3.0	33
74	Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis. Drug Design, Development and Therapy, 2013, 7, 131.	4.3	26
75	Targeting CD52 for the Treatment of Multiple Sclerosis. , 2013, , 385-399.		0
76	Antibody-mediated encephalitis: a treatable cause of schizophrenia. British Journal of Psychiatry, 2012, 200, 92-94.	2.8	94
77	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 298-304.	1.9	171
78	We are about to cure MS in the next 10 years, even though we do not know its cause: No. Multiple Sclerosis Journal, 2012, 18, 784-785.	3.0	0
79	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	13.7	1,041
80	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1829-1839.	13.7	1,040
81	A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood, 2011, 118, 6299-6305.	1.4	96
82	Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology, The, 2011, 10, 338-348.	10.2	125
83	Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology, 2011, 258, 686-688.	3.6	277
84	'Radiologically compatible CLIPPERS' may conceal a number of pathologies. Brain, 2011, 134, e187-e187.	7.6	33
85	Alemtuzumab in Multiple Sclerosis. Noropsikiyatri Arsivi, 2011, 48, 79-82.	0.7	1
86	Alemtuzumab for the treatment of multiple sclerosis. Future Neurology, 2010, 5, 177-188.	0.5	0
87	B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis. Journal of Clinical Immunology, 2010, 30, 99-105.	3.8	207
88	Mutations in the selenocysteine insertion sequenceâ€“binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. Journal of Clinical Investigation, 2010, 120, 4220-4235.	8.2	268
89	A Novel Strategy To Reduce the Immunogenicity of Biological Therapies. Journal of Immunology, 2010, 185, 763-768.	0.8	65
90	Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain, 2010, 133, 2232-2247.	7.6	152

#	Article	IF	Citations
91	New treatment strategies in multiple sclerosis. Experimental Neurology, 2010, 225, 34-39.	4.1	39
92	Monoclonal antibodies in multiple sclerosis treatment: current and future steps. Therapeutic Advances in Neurological Disorders, 2009, 2, 195-203.	3.5	17
93	Multiple sclerosis: THE BARE ESSENTIALS. Practical Neurology, 2009, 9, 118-126.	1.1	27
94	IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). Journal of Clinical Investigation, 2009, 119, 2052-61.	8.2	257
95	Multiple sclerosis. Lancet, The, 2008, 372, 1502-1517.	13.7	3,988
96	Campath-1H Treatment of Multiple Sclerosis. Neurodegenerative Diseases, 2008, 5, 27-31.	1.4	34
97	Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis. New England Journal of Medicine, 2008, 359, 1786-1801.	27.0	927
98	The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology, 2006, 253, 98-108.	3.6	469
99	Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) Tâ€„cells. European Journal of Immunology, 2005, 35, 3694-3703.	2.9	50
100	Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. European Journal of Immunology, 2005, 35, 3332-3342.	2.9	279
101	Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clinical Neurology and Neurosurgery, 2004, 106, 270-274.	1.4	90
102	Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. European Journal of Neuroscience, 2003, 18, 2527-2537.	2.6	73
103	Multiple sclerosis. Lancet, The, 2002, 359, 1221-1231.	13.7	1,792
104	Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Annals of Neurology, 1999, 46, 296-304.	5.3	494
105	Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet, The, 1999, 354, 1691-1695.	13.7	447
106	Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain, 1996, 119, 225-237.	7.6	249
107	Alemtuzumab to treat multiple sclerosis. , 0, , 393-398.		0
108	All manner of ingenuity and industry. Brain, 0, , .	7.6	0